{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T13:31:20Z","timestamp":1793626280518,"version":"4.5.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Associaci\u00f3 Catalana de les Neurofibromatosis"},{"DOI":"10.13039\/100008666","name":"Fundaci\u00f3 la Marat\u00f3 de TV3","doi-asserted-by":"publisher","award":["126\/C\/2020"],"award-info":[{"award-number":["126\/C\/2020"]}],"id":[{"id":"10.13039\/100008666","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003030","name":"Ag\u00e8ncia de Gesti\u00f3 d'Ajuts Universitaris i de Recerca","doi-asserted-by":"publisher","award":["SGR-Cat 2021-00967"],"award-info":[{"award-number":["SGR-Cat 2021-00967"]}],"id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI23\/00619"],"award-info":[{"award-number":["PI23\/00619"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neurofibromatosis type 1 is a genetic disease with an autosomal dominant pattern. One of its clinical features is the presence of disfiguring neurofibromas. Most adults with Neurofibromatosis type 1 have visible neurofibromas depending on the severity of their skin related clinic that can affect their body image, and body image influencing psychological assistance and social support. This research explored Body image, the negative perception of the appearance of neurofibromas and skin severity in Neurofibromatosis type 1 patients; assessed its association with quality of life; and the role of social support and psychological assistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Two hundred five patients with Neurofibromatosis type 1 (16\u201374\u00a0years) were included in the study. They responded to questionnaires about their quality of life, body image and other sociodemographic data. Correlations and simple and multiple regressions were used to assess the relationships between variables. The results showed that body image problems increased if Neurofibromatosis type 1 patients were concerned about the aspects of their neurofibromas (B\u2009=\u20094.544;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and if they had severe skin conditions (B\u2009=\u20094.262;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u2009.001). Despite this, statistical analysis showed that only body image impairments reduced quality of life by 0.605 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), while skin severity and the negative perception of the appearance of neurofibromas were not clearly related. Patients with body image impairments are more likely to seek psychological assistance (\u03c1\u2009=\u20090.218;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01), but they are less likely to report having social support. The results also showed that when patients with Neurofibromatosis type 1 retrieved they have social support (\u03c1\u2009=\u2009-0.210,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01) or they inform doing psychological assistance (\u03c1\u2009=\u2009-0.238;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), they have lower quality of life.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Body image concerns, rather than skin severity, are a key feature for detecting quality of life impairments in these patients. When healthcare professionals detect body image impairments, it is crucial for them to collaborate with patients and either provide or refer them to psychological interventions. This approach helps improve social support, enabling patients to benefit from both their professional and personal environments.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-025-03729-w","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T05:14:28Z","timestamp":1749186868000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The association of body image with quality of life, psychological assistance and social support in neurofibromatosis type 1 patients: a cross-sectional study"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-8816-8283","authenticated-orcid":false,"given":"Daniel","family":"Mu\u00f1oz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8913-5977","authenticated-orcid":false,"given":"Merc\u00e8","family":"Jodar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laia","family":"Valls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7944-7328","authenticated-orcid":false,"given":"Albert","family":"Fornieles-Deu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8133-5325","authenticated-orcid":false,"given":"Elisabeth","family":"Castellanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7414-7481","authenticated-orcid":false,"given":"Ignacio","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,6]]},"reference":[{"key":"3729_CR1","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1038\/s41436-021-01170-5","volume":"23","author":"E Legius","year":"2021","unstructured":"Legius E, Messiaen L, Wolkenstein P, Pancza P, Avery RA, Berman Y, et al. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genet Med. 2021;23:1506\u201313.","journal-title":"Genet Med"},{"key":"3729_CR2","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1212\/01.wnl.0000250332.89420.e6","volume":"68","author":"E Dombi","year":"2007","unstructured":"Dombi E, Solomon J, Gillespie AJ, Fox E, Balis FM, Patronas N, et al. NF1 plexiform neurofibroma growth rate by volumetric MRI: Relationship to age and body weight. Neurology. 2007;68:643\u20137.","journal-title":"Neurology"},{"key":"3729_CR3","doi-asserted-by":"publisher","first-page":"37","DOI":"10.5209\/PSIC.59173","volume":"15","author":"N Castrill\u00f3n","year":"2018","unstructured":"Castrill\u00f3n N, Blanco I. Conviviendo con la neurofibromatosis tipo 1: Revisi\u00f3n de la literatura. Psicooncologia. 2018;15:37\u201348.","journal-title":"Psicooncologia"},{"key":"3729_CR4","doi-asserted-by":"publisher","first-page":"E8","DOI":"10.3171\/2009.11.FOCUS09221","volume":"28","author":"ON Gottfried","year":"2010","unstructured":"Gottfried ON, Viskochil DH, Couldwell WT. Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications. Neurosurg Focus. 2010;28:E8.","journal-title":"Neurosurg Focus"},{"key":"3729_CR5","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1159\/000327379","volume":"222","author":"TA Duong","year":"2011","unstructured":"Duong TA, Bastuji-Garin S, Valeyrie-Allanore L, Sbidian E, Ferkal S, Wolkenstein P. Evolving pattern with age of cutaneous signs in neurofibromatosis type 1: a cross-sectional study of 728 patients. Dermatology. 2011;222:269\u201373.","journal-title":"Dermatology"},{"key":"3729_CR6","doi-asserted-by":"publisher","first-page":"883019","DOI":"10.3389\/fpsyg.2022.883019","volume":"13","author":"A Leidger","year":"2022","unstructured":"Leidger A, Vosschulte M, Nieder TO, Mautner VF. Sexual Self-esteem and psychological burden of adults with neurofibromatosis type 1. Front Psychol. 2022;13:883019.","journal-title":"Front Psychol"},{"key":"3729_CR7","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1159\/000337548","volume":"224","author":"S Granst\u00f6rm","year":"2012","unstructured":"Granst\u00f6rm S, Langenbruch A, Augustin M, Mautner VF. Psychological burden in adult neurofibromatosis type 1 patients: Impact of disease visibility on body image. Dermatology. 2012;224:160\u20137.","journal-title":"Dermatology"},{"key":"3729_CR8","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13023-023-02629-1","volume":"18","author":"H Fournier","year":"2023","unstructured":"Fournier H, Calcagni N, Morice-Picard F, Quintard B. Psychosocial implications of rare genetic skin diseases affecting appearance on daily life experiences, emotional state, self-perception and quality of life in adults: a systematic review. Orphanet J Rare Dis. 2023;18:39.","journal-title":"Orphanet J Rare Dis"},{"key":"3729_CR9","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1002\/pon.3350","volume":"22","author":"KB Smith","year":"2013","unstructured":"Smith KB, Wang DL, Plotkin SR, Park ER. Appearance concerns among women with neurofibromatosis: examining sexual\/bodily and social self-consciousness. Psychooncology. 2013;22:2711\u20139.","journal-title":"Psychooncology"},{"key":"3729_CR10","doi-asserted-by":"publisher","unstructured":"Thompson JK, Burke NL, Krawczyk R. Measurement of body image in adolescence and adulthood. Encyclopedia of body image and human appearance [Internet]. Elsevier; 2012. p. 512\u201320. https:\/\/doi.org\/10.1016\/B978-0-12-384925-0.00081-X","DOI":"10.1016\/B978-0-12-384925-0.00081-X"},{"key":"3729_CR11","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1007\/s10897-012-9527-5","volume":"22","author":"G Hummelvoll","year":"2013","unstructured":"Hummelvoll G, Antonsen KM. Young adults\u2019 experience of living with neurofibromatosis type 1. J Genet Couns. 2013;22:188\u201399.","journal-title":"J Genet Couns"},{"key":"3729_CR12","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1007\/s11136-018-2055-5","volume":"28","author":"JW Varni","year":"2019","unstructured":"Varni JW, Nutakki K, Swigonski NL. Pain, skin sensations symptoms, and cognitive functioning predictors of health-related quality of life in pediatric patients with neurofibromatosis type 1. Qual Life Res. 2019;28:1047\u201352.","journal-title":"Qual Life Res"},{"key":"3729_CR13","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1111\/bjd.18363","volume":"182","author":"G Bottesi","year":"2020","unstructured":"Bottesi G, Spoto A, Trevisson E, Zuccarello D, Vidotto G, Cassina M, et al. Dysfunctional coping is related to impaired skin-related quality of life and psychological distress in patients with neurofibromatosis type 1 with major skin involvement. Br J Dermatol. 2020;182:1449\u201357.","journal-title":"Br J Dermatol"},{"key":"3729_CR14","unstructured":"Hopwood P, Fletcher I, Lee A, Al Ghazal S. A body image scale for use with cancer patients. [cited 2023 Jan 12]. Available from: www.ejconline.com"},{"key":"3729_CR15","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s00520-014-2383-0","volume":"23","author":"P G\u00f3mez-Campelo","year":"2015","unstructured":"G\u00f3mez-Campelo P, Bragado-\u00c1lvarez C, Hern\u00e1ndez-Lloreda MJ, S\u00e1nchez-Bernardos ML. The Spanish version of the body image scale (S-BIS): psychometric properties in a sample of breast and gynaecological cancer patients. Support Care Cancer. 2015;23:473\u201381.","journal-title":"Support Care Cancer"},{"key":"3729_CR16","unstructured":"World health organization (WHO) [Internet]. 2023 [cited 2023 May 2]. Available from: https:\/\/www.who.int\/"},{"key":"3729_CR17","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1159\/000187594","volume":"218","author":"Y Kodra","year":"2009","unstructured":"Kodra Y, Giustini S, Divona L, Porciello R, Calvieri S, Wolkenstein P, et al. Health-related quality of life in patients with neurofibromatosis type 1: a survey of 129 Italian patients. Dermatology. 2009;218:215\u201320.","journal-title":"Dermatology"},{"key":"3729_CR18","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s11060-013-1195-2","volume":"114","author":"AM Vranceanu","year":"2013","unstructured":"Vranceanu AM, Merker VL, Park ER, Plotkin SR. Quality of life among adult patients with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis: a systematic review of the literature. J Neurooncol. 2013;114:257\u201362.","journal-title":"J Neurooncol"},{"key":"3729_CR19","doi-asserted-by":"publisher","first-page":"e0163290","DOI":"10.1371\/journal.pone.0163290","volume":"11","author":"T Nayir","year":"2016","unstructured":"Nayir T, Uskun E, Y\u00fcrekli MV, Devran H, \u00c7elik A, Okyay RA. Does body image affect quality of life?: a population based study. PLoS ONE. 2016;11:e0163290. https:\/\/doi.org\/10.1371\/journal.pone.0163290.","journal-title":"PLoS ONE"},{"key":"3729_CR20","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/ced.14867","volume":"47","author":"H Crawford","year":"2022","unstructured":"Crawford H, North K, Wilson MJ, Berman Y, McKelvey-Martin V, Morrison PJ, et al. Development and preliminary evaluation of the neurofibromatosis type 1 adult quality of life (NF1-AdQoL) questionnaire. Clin Exp Dermatol. 2022;47:271\u201381.","journal-title":"Clin Exp Dermatol"},{"key":"3729_CR21","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1007\/s10897-016-9944-y","volume":"25","author":"J Barke","year":"2016","unstructured":"Barke J, Coad J, Harcourt D. The role of appearance in adolescents\u2019 experiences of neurofibromatosis type 1: a survey of young people and parents. J Genet Couns. 2016;25:1054\u201362.","journal-title":"J Genet Couns"},{"key":"3729_CR22","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s12687-015-0247-z","volume":"7","author":"J Barke","year":"2016","unstructured":"Barke J, Coad J, Harcourt D. Parents\u2019 experiences of caring for a young person with neurofibromatosis type 1 (NF1): a qualitative study. J Community Genet. 2016;7:33\u20139.","journal-title":"J Community Genet"},{"key":"3729_CR23","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1177\/13591053231208619","volume":"29","author":"A Aghaei","year":"2023","unstructured":"Aghaei A, Herran K, Fanaei SA, Khalili M, Jayadev P. Lived experiences of neurofibromatosis type 1 patients: Social life, stigma, and intervention strategies. J Health Psychol. 2024;29:811\u201324.","journal-title":"J Health Psychol"},{"key":"3729_CR24","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/B978-0-12-820788-8.00013-4","volume-title":"Basic statistics with R","author":"SC Loftus","year":"2022","unstructured":"Loftus SC. Data collection: methods and concerns. In: Loftus SC, editor. Basic statistics with R. Amsterdam: Elsevier; 2022. p. 17\u201325."},{"key":"3729_CR25","first-page":"1","volume-title":"Statistics in Medicine","author":"RH Riffenburgh","year":"2012","unstructured":"Riffenburgh RH. Planning studies. In: Riffenburgh RH, editor. Statistics in Medicine. 3rd ed. San Diego: Elsevier; 2012. p. 1\u201326.","edition":"3"},{"issue":"Suppl","key":"3729_CR26","first-page":"79","volume":"112","author":"X Badia","year":"1999","unstructured":"Badia X, Roset M, Montserrat S, Herdman M, Segura A. The Spanish version of EuroQol: a description and its applications. European quality of life scale. Med Clin (Barc). 1999;112(Suppl):79\u201385.","journal-title":"Med Clin (Barc)"},{"key":"3729_CR27","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"EuroQol Group","year":"1990","unstructured":"EuroQol Group. EuroQol\u2014a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199\u2013208.","journal-title":"Health Policy"},{"key":"3729_CR28","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S0212-6567(01)70406-4","volume":"28","author":"M Herdman","year":"2001","unstructured":"Herdman M, Badia X, Berra S. EuroQol-5D: a simple alternative for measuring health-related quality of life in primary care]. Aten primaria. 2001;28:425\u201330.","journal-title":"Aten primaria"},{"key":"3729_CR29","doi-asserted-by":"publisher","first-page":"70","DOI":"10.2146\/ajhp070006","volume":"66","author":"JE De Muth","year":"2009","unstructured":"De Muth JE. Overview of biostatistics used in clinical research. Heal Pharm Am J Health Syst Pharm. 2009;66:70\u201381.","journal-title":"Heal Pharm Am J Health Syst Pharm"},{"key":"3729_CR30","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.6018\/analesps.30.3.199361","volume":"30","author":"S Lloret-Segura","year":"2014","unstructured":"Lloret-Segura S, Ferreres-Traver A, Hern\u00e1ndez-Baeza A, Tom\u00e1s-Marco I. El an\u00e1lisis factorial exploratorio de los \u00edtems: Una gu\u00eda pr\u00e1ctica, revisada y actualizada. An Psicol. 2014;30:1151\u201369.","journal-title":"An Psicol"},{"key":"3729_CR31","doi-asserted-by":"publisher","first-page":"417","DOI":"10.6018\/analesps.33.2.270211","volume":"33","author":"S Lloret-Segura","year":"2017","unstructured":"Lloret-Segura S, Ferreres A, Tom\u00e1s AH. El an\u00e1lisis factorial exploratorio de los \u00edtems: An\u00e1lisis guiado seg\u00fan los datos emp\u00edricos y el software. An Psicol. 2017;33:417\u201332.","journal-title":"An Psicol"},{"key":"3729_CR32","unstructured":"Bishop YMM, Holland P, Fienberg SE. Discrete multivariate analysis: Theory and Practice. 1975."},{"key":"3729_CR33","volume-title":"Applied regression analysis and other multivariable methods","author":"DG Kleinbaum","year":"2013","unstructured":"Kleinbaum DG, K\u00fcpper LL, Muller KE, Nizam A. Applied regression analysis and other multivariable methods. Pacific Groove: Duxbury Applied Press; 2013."},{"key":"3729_CR34","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1002\/wps.20238","volume":"14","author":"BE Wampold","year":"2015","unstructured":"Wampold BE. How important are the common factors in psychotherapy? An update. World Psychiatry. 2015;14:270\u20137.","journal-title":"World Psychiatry"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03729-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03729-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03729-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T13:03:30Z","timestamp":1793624610000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03729-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,6]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3729"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03729-w","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,6]]},"assertion":[{"value":"22 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Following publication of the original article, wehave been notified that funding note was published incorrectly. It is now: This study has been funded by Fundaci\u00f3 La Marat\u00f3 de TV3 (126\/C\/2020), Associaci\u00f3 Catalana de les Neurofibromatosis (ACNeFi), the Government of Catalonia (SGR-Cat 2021-00967), and by ISCIII (PI23\/00619) (Co-funded by\nEuropean Regional Development Fund \"A way to make Europe\"). It should be: This study has been funded by the Instituto de Salud Carlos III (AC22\/00033) through the NextGeneration EU funds, financing the actions of the Recovery and Resilience Mechanism (MRR). This study has been funded by Fundaci\u00f3 La Marat\u00f3 de TV3 (126\/C\/2020), Associaci\u00f3 Catalana de les Neurofibromatosis (ACNeFi), the Government of Catalonia (SGR-Cat 2021-00967), and by ISCIII (PI23\/00619) (Co-funded by\nEuropean Regional Development Fund \"A way to make Europe\")","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Ethics Research Committee of the Germans Trias i Pujol Hospital and was conducted in accordance with the latest version of the ethical principles of the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The terms regarding publication are included in the consent approved by the Ethics Research Committee of the Germans Trias i Pujol. All data published are anonymous.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"284"}}